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Abstract.  The plasma membranes of the nerve termi- 
nal and the postsynaptic cell of electric organ are 
separated by a basal lamina.  We have purified, bio- 
chemically characterized,  and visualized in the elec- 
tron microscope a macromolecule which appears to 
anchor the nerve terminal to this basal lamina.  This 
molecule, terminal anchorage protein  1 (TAP-l) is as- 
sociated with the nerve terminal membrane of electric 
organ, has the properties of an integral membrane pro- 
tein, and is tightly bound to the extracellular matrix 
(Carlson,  S.  S., P. Caroni,  and R. B. Kelly.  1986. J. 
Cell Biol. 103:509-520).  TAP-1 can be solubilized 
from an electric organ extracellular matrix preparation 
with guanidine-HCl/3-[(3-cholamidopropyl)-dimethyl- 
amnmio]-l-propane  sulfonate and purified by a combi- 
nation of permeation chromatography on Sephacryl 
S-1000, sedimentation velocity, and ion exchange chro- 
matography on DEAE Sephacel.  The total  purification 
from electric organ is 91-fold and results in at least 
86% purity.  Digestion of the molecule with chondroi- 
tin ABC or AC lyase produces a large but similar shift 
in the molecular weight of the molecule on SDS- 
PAGE.  The presence of chondroitin-4- or 6-sulfate is 
confirmed by identification of the isolated glycosami- 
noglycans with cellulose acetate electrophoresis.  Gel 
filtration of the isolated chains indicates an average 
molecular weight of 42,000.  Digestion of TAP-1 with 
other glycosaminoglycan lyases such as heparitinase 
indicates that only chondroitin sulfate is present. 
These results demonstrate that TAP-1 is a proteogly- 
can.  Visualization of TAP-1 in the electron microscope 
reveals a "bottlebrush" structure expected for a pro- 
teoglycan. The molecule has an average total length of 
345  •  17 nm with 20  •  2 side projections of 113  • 
5 nm in length.  These side projections are presumably 
the glycosaminoglycan side chains.  From this struc- 
ture,  we predict that the TAP-1 glycosaminoglycan side 
chains should have a molecular weight of •50,000, 
which is in close agreement with the biochemical 
studies. Both biochemical and morphologic data indi- 
cate that TAP-1 has a relative molecular weight of 
=1.2  x  106. The large size of TAP-1 suggests that this 
molecule could span the synaptic cleft and make a 
significant contribution to the structure of the nerve 
terminal basal lamina of electric organ. 
!  I~'~nF.  synaptic  extracellular  matrix  (ECM)  is capable 
I  of directing the precise rebuilding  of the nerve termi- 
nal during  nerve regeneration  at the neuromuscular 
junction (Sanes et al., 1978; Sanes and Chiu, 1983; Sanes and 
Covault,  1985). The presence of a muscle fiber is not re- 
quired during rebuilding.  In muscle damaged so that it con- 
rains empty basal lamina sheaths without muscle fibers, the 
regenerating axon can locate the original synaptic site and re- 
form a mature nerve terminal.  A high percentage  of these 
nerve terminals formed on empty synaptic basal lamina show 
precise rebuilding.  The exocytotic zones of the presynaptic 
plasma membrane are reconstructed at their original position 
on the basal lamina (Sanes et al., 1978; Glickman and Sanes, 
1.  Abbreviations  used  in  this paper:  CHAPS,  3-[(3-cholamidopropyl)- 
dimethylammnio] 1-propane sulfonate;  ECM, extracellular  matrix; GAG, 
glycosaminoglycan;  SV4, synaptic vesicle antigen 4; TAP-l,  terminal an- 
chorage protein 1. 
1983). Thus, components of the original synaptic basal lam- 
ina  provide both identification  cues as well as a  synaptic 
foundation  on which to build a new nerve terminal.  These 
synaptic  ECM components are presumably recognized  by 
membrane proteins of the returning axon during the rebuild- 
ing process. Integral membrane proteins that link the mature 
nerve terminal  to the synaptic basal lamina,  nerve terminal 
anchorage proteins (Kelly et al., 1987), are likely candidates 
in this recognition.  However, identification  and purification 
of anchorage proteins  from the neuromuscular junction is a 
formidable  task,  given  the  minute  quantities  of material 
available. 
The electric organ of marine rays contains  an abundance 
of synapses  embryologicaUy  related to the neuromuscular 
junction. This tissue has served as a rich source of synaptic 
macromolecules,  such as an ECM  factor involved  in  the 
clustering of acetylcholine receptor and acetylcholinesterase 
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cule with the properties of a nerve terminal anchorage pro- 
tein has been identified in electric organ (Carlson et al., 
1986). This molecule is found on the nerve terminal surface, 
behaves  as  an  integral membrane protein,  and  is  tightly 
bound to an electric organ ECM fraction. However, the exact 
chemical nature of this molecule is not known. We now re- 
port the complete purification and characterization of this 
anchorage protein, called TAP-1 (terminal anchorage protein 
1). TAP-1 under denaturing conditions is a large proteogly- 
can (relative molecular weight of ~1.2 million) containing 
chondroitin-4- or 6-sulfate side chains with a relative molec- 
ular weight =42,000. When visualized in the electron micro- 
scope,  TAP-1 has the typical proteoglycan "bottle brush" 
morphology with dimensions of ,x,3,500 x  2,100/~. A syn- 
aptic molecule of this size could easily span the =600-A dis- 
tance of the synaptic cleft and substantially contribute to the 
structure of the synaptic basal lamina. 
Materials and Methods 
Materials 
Na~ZSI was obtained from Amersham Corp. (Arlington Heights, IL); ultra- 
pure urea from SehwarzlMann Div., Becton, Dickinson & Co. (Spring Val- 
ley,  NY);  3-[(3-cholamidopropyl)-dimethylammnio]t-propane  sulfonate 
(CHAPS), Hepes, SDS, diisopropylfiuorophorophosphate, iodoacetamide, 
pepstatin,  leupeptin,  chymostatin,  guanidine-HC1,  heparin,  chondroitin 
sulfates A, 13, and C, from Sigma Chemical Co. (St. Louis, MO); keratan 
sulfate and heparan sulfate from Miles Scientific (Naperville, IL). The elec- 
tric ray, Discopyge ommata, was obtained from Marinus Inc. (Long Beach, 
CA). 
Purification of TAP-1 
TAP-1 was detected with a monoclonal antibody (mAb) directed against the 
synaptic vesicle antigen 4  (SV4) antigenic site in a nitrocellulose dot blot 
assay described previously (Carlson et al.,  1986).  This assay  was used 
throughout the purification to determine the TAP-t concentration in the vari- 
ous fractions. 
The progress of the purification was follo~at by monitoring the specific 
activity (i.e., TAP-1 antigenicity per microgram of protein) of the fractions 
generated by the isolation scheme. However, when measuring TAP-l, most 
protein assays were found to be too insensitive. Thus, a modified version 
of the filter-binding assay of Schaffer and Weissmann (1973) was used. The 
modifications were as follows. All sample dilutions were done in 8 M urea, 
0.2% CHAPS, 50 mM Hepes, pH 7.0. After the sample was applied to the 
nitrocellulose (0.45 Ixm) using a Bio-Dot microfiltration apparatus (Bio-Rad 
Laboratories, Richmond, CA), the nitrocellulose was stained overnight in 
1 ttl/ml India ink, 0.4 M NaCI,  10 mM Hepes, 0.3% Tween 20, pH 7.0. As 
indicated by Hancock and Tsang (1983), the India ink must be Pelikan fount 
India drawing ink for fountain pens (Pelikan AG, Hanover, Federal Republic 
of Germany).  The nitrocellulose was dried on a Slab Gel dryer (Hoefer 
Scientific Instruments, San Francisco, CA), and the stained samples on the 
nitrocellulose were quantitated with a Zeineh soft laser scanning densitome- 
ter, model SL-504-XL 03iomed Instruments, Inc., Fullerton, CA). A sam- 
ple containing ECM proteins of known concentration was used as a standard 
in the assay. The assay was linear from 10 to 1(30 ng of protein. 
The starting material for the TAP-1 preparation was an ECM preparation 
from electric organ (Carlson et al., 1986).  The ECM pellet was solubilized 
by mixing each gram with 2 ml of 6 M guanidine-HCl, 2% CHAPS, 50 mM 
Hepes,  10 mM EDTA, 0.02 % sodium azide, pH 7.0. All solutions used in 
the purification were Millipore filtered (0.45 txm, Millipore Corp., Bedford, 
MA) before use. For each gram of pellet the following protease inhibitors 
were also added:  12 nag of iodoacetamide, 2.5 ~1 of diisopropylfluorophos- 
phate, and 25 p.l of dimethylsuifoxide containing pepstatin, leupeptin, and 
chymostatin at 5 m_g/ml. A homogenate was then generated with a Folytron 
(Brinkmann Instruments Co., Westbury, NY), using three 10-s bursts If) min 
apart at 4~  The homogenate was then mixed by rotation for 1 h; 6  I.tl of 
~mercaptoethanol/g ECM pellet was added, then given 30 rnin more rota- 
tion mixing, and finally spun at 12,096 g  for 30 min at 4"C. 
All of the remaining purification steps were performed at room tempera- 
ture. The 40-50 ml of ECM  12,096 g  supernatant (obtained from *300 g 
of electric organ) were applied to a 2.4-liter Sephacryl S-1000 column (5 x 
122  cm)  equilibrated  with  4  M  guanidine-HCI,  50  mM  Hepes,  0.2% 
CHAPS,  10 mM EDTA, 0.02% sodium azide, pH Z0, 100 mg/liter of iodo- 
acetamide, 8  gl/liter of diisopropylfluorophosphate, and 50 I.tl/liter  of di- 
methylsulfoxide containing 5 mg/ml each of pepstatin, leupeptin, and chymo- 
statin (Sigma Chemical Co.). The flow rate was 50 ml/h and 17-ml fractions 
were collected. The peak fractions containing the highest specific activity 
(antigenicity per microgram protein) of TAP-1  were pooled and concen- 
trated to a volume of •15  ml with a YM 30 membrane in an Amicon Stirred 
Cell (Amicon Corp., Danvers, MA). Before concentration, protease inhibi- 
tors were added: for each milliliter of the pooled fractions, 0.5 mg of iodo- 
acetamide, 0.04 ~t of diisopropylfluorophosphate, 0.25 p.1 of dimethylsul- 
foxide containing 5 mg/ml each of pepstatin, leupeptin, and chymostatin. 
The concentrated pool of Sephacryl S-1000  fractions containing TAP-t 
was spun at 12,500 g for 15 min, and the resulting supernatant was subjected 
to sedimentation velocity centrifugation on 35.5 ml of 5-20% sucrose gra- 
dients containing all the constituents of the Sephacryl S-1000 column buffer. 
3 ml of the concentrated pool was applied to each gradient. Typically about 
five gradients were run for 300 g of starting electric organ tissue. The gra- 
dients were spun at 20~  for 18 h at 25,000 rpm in an SW-28 rotor (Beckman 
Instruments, Inc., Fullerton, CA), and 1.5-ml fractions were collected for 
each gradient.  The peak fractions containing the highest specific activity 
(antigenicity per microgram of protein) from all the gradients were pooled 
and concentrated to 3-4 ml as described above. 
For the last step in the purification, the concentrated TAP-1 solution ob- 
tained from sedimentation velocity centrifugation was chromatographed on 
DEAE Sephacel. The concentrated sample was spun at 12,500 g  and the 
resulting supernatant diluted  1:40 with a  solution containing 8  M  urea, 
0.11 M NaCI, 50 mM sodium acetate, 0.2% CHAPS, 2 mM E~A,  0.02% 
sodium azide, 0.05 p.g/ml iodoacetamide, and 0.04 Ixllml diisopropylfluoro- 
phosphate, pH 4.9. The diluted sample was applied by reverse flow to an 
8 ml (0.5 x  10 cm) DEAE Sephacel column equilibrated with the same 8 M 
urea buffer used for the dilution. The column was then washed with 150 ml 
of this equilibration buffer and eluted in the forward direction with a 150-ml 
linear NaCI gradient. The gradient was formed with 75 mi of the equilibra- 
tion buffer and 75 ml of equilibration buffer containing 1.4 M NaCI (instead 
of 0.11 M).  2-ml fractions were collected at a flow rate of m30 ml/h. 
SDS-PAGE of Glycosaminoglycan 
Lyase-digested TAP-1 
TAP-1 was subjected to SDS-PAGE to evaluate purity of the TAP-I prepara- 
tion and determine the effects of glycosaminoglycan lyase digestion. 
TAP-I  was iodinated with ~I as previously described (Carlson et al., 
1986) either in a solution of 8 M  urea, 0.2% CHAPs, 50 mM Hepes, pH 
7.0, or the same solution with 4  M  guanidine-HCl rather than urea. Both 
completely purified TAP-1 (purified through the DEAE sephacel step) and 
partially purified material (purified through the sedimentation velocity step) 
were iodinated. In some cases partially purified Iz~I-TAP-1 was completely 
purified by the DEAE Sephacel step of the purification or by immunoprecip- 
itation with the anti-SV4 mAb. 
To digest ~zSI-TAP-1 with chondroitin ABC lyase, procedures similar to 
those of Oike et al. (1980) were used. The reaction mixture (20-30 ~tl, total 
volume)  contained 0.1-0.01  ~g  of  J2SI-TAP-1, 5-10  U/ml  of chondroitin 
ABC  lyase (Miles Scientific), 94 mM Tris/HCI,  pH 8.0,  9  mM EDTA, 
0.19%  CHAPS,  0.05  mg/ml BSA, 0.9 mg/ml iodoacetamide,  0.4 mg/ml 
phenylmethanesulphonyl fluoride, and 0.1 mg/ml each of pepstatin, leupep- 
tin, and chymostatin. (BSA and these prot_ease !nhibitors were added to pre- 
vent possible digestion of TAP-I  by contaminating proteases.  On  SDS- 
PAGE, the BSA showed no evidence of protease activity during any of the 
digestions.) The I~I-TAP-1 was in 4  M gnanidine-HCl, 8 M urea or 0.5% 
SDS before a 1:16 dilution into this reaction mixture. The digestion was car- 
ried out at room temperature for 3 h, then terminated by boiling after adding 
20 Ixl of 4.8%  SDS,  0.11 M  Tris/HCl,  18%  glycerol,  9.2%  I~-mereapto- 
ethanol, 0.002 % bromophenol blue, pH 6.8. Digestions of 12SI-TAP-1 with 
chondroitin AC lyase (Miles Scientific) and keratanase (Miles Scientific) 
were done under the same conditions but at pH 7.4 and at concentrations 
of 9  U/ml and 2-5  U/ml respectively.  Heparinase (Miles Scientific) and 
heparitinase (Miles Scientific) digestions of a25I-TAP-1 were performed at 
pH 7.0, in 47 mM Hepes, 2 mM calcium acetate,  19% CHAPS at enzyme 
concentrations of 13-25 U/ml; all other conditions were the same as used 
for chondroitin ABC lyase digestions. When cbondroitin ABC lyase was 
used  in combination with other glycosaminoglycan lyases,  the digestion 
conditions of the other enzyme were used. In order to be sure a glycosami- 
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a separate digestion was done with the enzyme and its substrate at a concen- 
tration of 2  ~tg of glycosaminoglycan (GAG)/~tl.  The products of these 
digestions were analysed by  cellulose acetate electrophoresis (Carlson, 
1982) and stained with Alcian blue (Kanwar and Farquhar,  1979). 
When chondroitin ABC lyase was used in combination with N-glycanase 
(Genzyme Corp., Boston, MA) to digest TAP-I, the chondroitin ABC lyase 
reaction buffer was used with the exception that 40 mM sodium phosphate, 
pH 8.6, was substituted for 94 mM Tris/HCl. N-glycanase was used at a con- 
centration of 27 U/nil and the reaction was carried out at room temperature 
for 24 h. When TAP-I  was digested with both chondroitin ABC lyase and 
neuraminidase-Vibrio  cholerae  (Calbiochem-Behring Corp.,  San  Diego, 
CA), the digestions were performed sequentially. First the chondroitin ABC 
lyase digestion was carried out as described before, except that 38  mM 
Tris/HCI, pH 8.0, was used instead of 94 mM, and no EDTA was present. 
After a 3-h incubation at room temperature 270 ~tl of  75 mM sodium acetate, 
2 mM calcium acetate, 0.2 mM EDTA, pH 5.0, and 10 ~tl of 1 U/ml of neur- 
aminidase were added to the 30-~tl reaction mixture. The reaction was in- 
cubated for 24 h at room temperature and then concentrated to 100 ttl with 
a Centricon-30 (Amicon Corp.). 500 Ixl of 0.05%  SDS, 0.1 M NH4HCO4 
was added to the Centricon-30 and the resulting 600 I~1 was concentrated 
to  100 ~tl. The sample was then dried in preparation for SDS-PAGE. 
Chondroitin ABC lyase digestions were also performed on TAP-1 which 
had been immunoprecipitated with the anti-SV4 mAb. To immunoprecipi- 
tate  TAP-I,  the  ~25I-labeled material  was  diluted  sevenfold with 0.2  M 
NaCI, 10 mM Hepes, 1% SDS, pH 7.0, and incubated 30 min at room tem- 
perature. The sample was diluted another 22-fold with 0.4 M NaC1,  10 mM 
Hepes, 1.5 % Triton X-100, 0.1% BSA, pH 7.0, and then immunoprecipitated 
with Immunobeads (Bio-Rad Laboratories) to which the anti-SV4 mAb had 
been previously bound.  These procedures were as previously described 
(Carlson et al., 1986). The antigen was then freed from the immunobeads 
by boiling the resuspended beads in 0.2 M NaCI, 10 mM Hepes, 0.5 % SDS, 
pH 7.0, for 2 min. After removing the beads with a 12,000-g centrifugation 
for 10 min, an aliquot from the resulting supernatant was diluted about 1:16 
with the chondroitinase reaction mixture containing 0.47 % Triton X-100 in- 
stead of 0.19% CHAPS. The chondroitin ABC lyase digestion was then car- 
ried out as described above. 
SDS polyacrylamide slab gel electrophoresis was performed with the 
buffer system described by Laemmli (1970). The gels were composed of a 
2.4-8 % linear gradient of  acrylamide with a 2.4 % stacking gel on a backing 
of GelBond (FMC Corp. Rockland, ME). Autoradiography was performed 
and the results quantified as previously described for dot blots (Carlson et 
al.,  1986). 
Preparation and Analysis of  GAGs  frora TAP-1 
GAGs were cleaved from TAP-1 with alkaline borohydride. The method was 
a  slight modification of Carlson (1968).  The TAP-1 solution (containing 
80-600 ~tg of GAG) was concentrated to 190 Ixl and the salts of the solution 
were exchanged for4 M guaoidine, 0.2% CHAPS with a Centricon-30. The 
concentrated TAP-I  sample was mixed with  110 txl of 0.5  M  NaOH and 
800 I.tl of 1.38 M  sodium borohydride and heated to 45~  for 48 h. The 
reaction was terminated by adding 60 I.tl of concentrated acetic acid. The 
excess hydrogen gas was removed from the sample by evaporation for 10 min 
on a Speed-Vac  (Savant  Instruments, Inc., Hicksville, NY).  The reaction 
mixture was then either dialyzed overnight (Spectra/Por 7, molecular weight 
cutoff3,500, Spectrum Scientific, Inc., Houston, TX) against 2 liters 50 mM 
NI-LHCO3 (two changes outer solution), or it was applied to a Sepharose 
CL-6B column. 
30 ~tl of a 5 mg/ml Phenol Red was added to the alkaline borohydride- 
treated TAP-I  as a chromatographic marker, =l-ml sample was applied to 
a Sepharose CL-6B column (133  x  0.7 cm), and the chromatography was 
carried out according to Wasteson (1971). The column buffer was prefiltered 
through DEAE nitrocellulose to reduce the background in the nitrocellu- 
lose-binding assay used to detect GAGs (see below). The Kay values for the 
half-height of the leading and trailing edges, as well as the central peak of 
the TAP-1 GAG chains were determined from the elution profile. The molec- 
ular weights corresponding to these elution volumes were then determined 
by using the calibration curves of Wasteson (1971) for chondroitin sulfate 
chains. 
A nitrocellulose-binding assay was used to determine the GAG content 
of various column fractions which resulted during the chromatographic 
analysis of the isolated TAP-1 GAG side chains as well as during the TAP-1 
purification. This assay for GAGs involves binding the samples to DEAE 
nitrocellulose and  staining the paper with Alcian blue.  For samples in 
guanidine-HC1 or urea solutions, the DEAE nitrocellulose sheet was wetted 
with 6 M urea, 0.1 M NaCI, 0.2% CHAPS, 20 mM Hepes, 0.02%  sodium 
azide, pH 7.3; the sheet was placed in the dot-blot manifold (see protein as- 
say) above a sheet of regular nitrocellulose (for structural support); and the 
samples (diluted to 200-1,000 Ixl with the same buffer) were spotted. Sam- 
pies in nondenaturing solutions were diluted in 0.1 M NaCI, 25 mM Hepes, 
pH 7.0. All samples were diluted until their conductivity was approximately 
equal to 0.1 M NaCI ("o1:40 for 4 M gnanidine-HCl). All solutions used 
for the dilution of samples were prefiltered through DEAE nitrocdiniose. 
After the samples were spotted, the DEAE nitrocellulose was removed from 
the manifold, soaked in 95 % ethanol for •20  s, and air dried. To stain the 
spotted samples, the dried DEAE nitrocellulose was soaked in 0.1% Alcian 
blue, 50 mM sodium acetate, pH 7.0, for 1 h, then destained overnight in 
50 mM sodium acetate, pH 7.0, with three to four changes of solution. The 
DEAE  nitrocellulose was dried  and  the stained samples qnantitated as 
described for the protein assay. The assay was linear from 100-1,000 ng of 
heparin. The assay showed a specificity for GAGs over protein of at least 
20 to 1. That is, chrondroitin sulfate (type c) is stained 23 times more in- 
tensely per microgram than  several purified proteins (BSA,  ovalbumin, 
trypsin, and IgG). 
In order to identify the GAGs of TAP-I, the isolated chains were subjected 
to cellulose acetate electrophoresis. The peak fractions from the Sepharose 
CL 6B chromatography were pooled, dialyzed against 50 mM NtLHCO3, 
and lyophilized. Cellulose acetate electrophoresis, the staining of  these elec- 
trophoretograms with mRuthenium Red, and quantitation of the resulting 
autoradiograms were performed as previously described (Carlson, 1982). 
Electron Microscopy 
Samples of purified TAP-I (100 ttg/ml) in 8 M urea, 50 mM sodium acetate, 
0.65 M NaCI, 0.2% CHAPS, 2 mM EDTA, pH 4.9, were diluted 1:20 with 
1 M  ammonium acetate buffer, pH 5.0, to give a  final concentration of 
5 ttg/ml protein. The sample was then mixed 1:1 with 0.01 M Tris, 0.01 M 
EDTA, pH 8.5, and enough of the following solution containing 25 mg/ml 
cytochrome c (Horse heart type HI, Sigma Chemical Co.), 2 M Tris/HC1, 
0.05 M EDTA, pH 8.5, was added to give a final concentration of  62.5 ttg/ml 
cytochrome c. A 75-ttl aliquot of sample was run continuously down a wet 
glass slide onto a deionized water surface. After spreading for 15  s, the 
monolayer film was touched by carbon stabilized Parlodian-coated grids and 
stained immediately with 0.001% phosphotungstic acid in 90% ethanol for 
5 s and 5  ￿  10  -5 M uranyl acetate in 90% ethanol. After an alcohol rinse, 
the grids were air dried and rotary shadowed with platinum/palladium at 
an angle of 10 ~ and a distance of 8 cm. Grids were examined with a JEOL 
1130 B electron microscope and photographed at a magnification of 25,000. 
Magnifications were calibrated by using a Pelco magnification-calibration 
grid (Pelco, Reading, CA). 
Results 
Purification of TAP-1 
Previously it has been shown that an antigenic determinant 
(SV4)  identified by a monoclonal antibody is present on a 
synaptic  vesicle proteoglycan and on another much larger 
protein in the ECM of electric organ (Carlson et al.,  1986). 
This ECM protein also has the charge characteristics  of a 
proteoglycan. It requires high salt (=0.7 M NaCI) to elute it 
from DEAE Sephacel. This molecule, called TAP-l, is found 
enriched in an electric organ ECM fraction from which it can 
be solubilized with 4 M guartidine-HC1 and CHAPS (Carl- 
son et al.,  1986).  Only low amounts of the synaptic  vesicle 
proteoglycan are found in this fraction (Iwata, M., and S. S. 
Carlson, unpublished observations).  Thus, this ECM frac- 
tion serves as a good starting material for the purification of 
TAP-1. 
The scheme determined for the purification of TAP-1 from 
the  ECM  fraction  involves  three  separation  methods:  (a) 
permeation chromatography  on Sephacryl S-1000,  (b) sedi- 
mentation velocity on sucrose density gradients,  and (c) ion 
exchange chromatography  on DEAE Sephacel. The purifica- 
tion is performed under denaturing  conditions; 4 M guani- 
dine-HCl with 0.2% CHAPS for steps a and b, and 8 M urea 
Carlson and Wight Nerve Terminal Anchorage Protein  3077 Table L Purification of TAP-l* 
Antigenicityr per 
Purification step  gram electric  organ  Recovery  Specific  activity  Fold purification 
cpm 
Electric  organw  221  ￿  10511 
ECM extract  185  x  l0  s 
Sepharose S-1000 column 
Peak  fractions  18.1  x  los 
Side fractions  18.3  x  los 
Velocity  sedimentation 
Peak  fractions  4.3  x  los 
Side fractions  4.8  ￿  lO  s 
Chromatography on DEAE Sephacel 
Peak fractions  0.91  x  l0  s 
%  cpm/#g protein 
100  1,318  1 






16,350  +  2,044'1  12.4 
ND  ND 
52,603  +  8,483'1  40 
ND  ND 
120,000  +  29,2001  91 
ND, not determined. 
* The data presented in this table represent three to four separate TAP-I preparations. 
* Antigenicity was measured with nitrocellulose dot-blot assay (see Materials and Methods). The units are counts per minute of ~251-goat  anti-mouse IgG bound 
to the nitrocellulose filter. The primary antibody (the anti-SV4 mAb) is present at saturating concentrations. Separate dot-blot assays are normalized to one another 
by spotting a concentration series of a known TAP-I solution. 
w  6 M guanidine/CHAPS extract of electric organ. 
II The antigenic site (SV4)  used to detect TAP-I is also present on a synaptic vesicle proteoglycan (Carlson et al.,  1986).  Further, the 6 M guanidine/CHAPS 
extract contains both TAP-1 and the synaptic vesicle proteoglycan. To determine the total amount of TAP-1 in the extract, using SV4 antigenicity, the total amount 
of synaptic vesicle proteoglycan in the extract also had to be determined. This was done with a monoclonal antibody directed against an antigenic determinant 
(SV 1) present only on the synaptic vesicle proteoglycan (Caroni et al., 1985). The total TAP-1 antigenicity was then calculated by correcting the total SV4 antigenic- 
ity in the extract for that contributed by the synaptic vesicle proteoglycan. In the ECM fraction the synaptic vesicle proteoglycan is only present in low amounts 
(Caroni et al., 1985; Carlson et al., 1986; lwata, M., and S. S. Carlson, unpublished observations); therefore, this correction is not important for the subsequent 
steps of the purification. 
'1 +  standard error of the mean. 
with 0.2 % CHAPS for the last step. Throughout the purifica- 
tion, the TAP-1 content of the resulting fractions was deter- 
mined by using the monoclonal antibody which binds the 
SV4 epitope in a dot-blot assay. Table I outlines the purifica- 
tion, the yield, and specific activity (antigenicity per micro- 
gram of protein) at each step. 
The ECM fraction is an insoluble pellet made from elec- 
tric organ by a series of high salt, low salt, and detergent ex- 
tractions of electric organ tissue (Carlson et al.,  1986). The 
components of this ECM pellet, including TAP-l, were solu- 
bilized by dissolving the fraction in 6 M guanidine-HCl/2 % 
CHAPS. As shown in Table I, TAP-1 was enriched fivefold 
in the ECM fraction over the starting tissue and the recovery 
is 84%. 
The next step in the purification of TAP-I is the fraction- 
ation by gel filtration on Sephacryl S-1000 of  the ECM guani- 
dine-HCI/CHAPS extract. The elution profile which results 
was essentially the same as that previously described (Carl- 
son et al.,  1986).  The peak fractions represented 8.2%  of 
the TAP-I present in the starting tissue and the increase in 
purification was  12.4-fold (Table I). 
The fourth step in the purification involves velocity sedi- 
mentation centrifugation. The peak fractions from Sepha- 
cryl S-1000 chromatography of TAP-1 were pooled, concen- 
trated, layered on a 5-20% sucrose gradient containing 4 M 
guanidine/CHAPS, and sedimented for 18 h at 83,000 g. Un- 
der these conditions as shown in Fig.  1, the majority of the 
TAP-1 sedimented to the bottom half of the gradient while 
the majority of the material containing GAGs remained in the 
upper half. The majority of the protein also remained in the 
upper half of the gradient (data not shown). The TAP-1 con- 
tained in the peak fractions has been purified 40-fold and rep- 
resented 1.9%  of the starting material (Table I). 
Ion exchange chromatography of TAP-1 on DEAE Sepha- 
cel was used as the last step in the purification. The peak 
fractions from the previous step were pooled, concentrated, 
and diluted  1:40  in 8  M  urea/CHAPS to reduce the ionic 
strength. The diluted TAP-1 solution was loaded on a DEAE 
Sephacel column which was subsequently eluted with a lin- 
ear 0.11-1.4 M NaC1 gradient at pH 4.9. The elution profile 
of one such column is shown in Fig. 2. All of the TAP-1 anti- 
genicity, protein, and material containing GAGs eluted as a 
single peak at about 0.70 +  .02 (SEM) M  NaC1.  The ratio 
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Figure 1. Preparative sedimentation  velocity centrifugation  of TAP-1. 
(o) TAP-1 antigenicity and (A) GAG concentration. The direction 
of the sedimentation is from right to left. 3 ml of a concentrated 
TAP-1 solution (isolated by chromatography on Sephacryl S-1000) 
was applied to a 35.5 ml of  5-20% sucrose gradient containing 4 M 
guanidine-HCl,  0.2%  CHAPS,  50 mM Hepes,  10 mM EDTA, 
0.02 % sodium azide, pH 7.0, and protease inhibitors. The gradients 
were spun at 83,000 g, 20~  for 18 h, and 1.5-ml fractions were 
collected. Each point on the figure represents two determinations 
of TAP-1 antigenicity and three for the GAG concentration. For 
more experimental details see Materials and Methods. 
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Figure 2. TAP-I elution profile for preparative ion exchange chromatography on DEAF_. Sephacel. (￿9 TAP-1 antigenicity, (zx)  GAG concen- 
tration, (,,) protein concentration, and (￿9 NaCI concentration. 2.8 ml of a concentrated TAP-1 solution (isolated by preparative sedimen- 
tation velocity centrifugation) was diluted 40-fold with 8 M urea, 0.11 M NaCI, 50 mM sodium acetate, 0.2% CHAPS, 2 mM EDTA, 
0.02% sodium azide, 0.05 ~tg/ml iodoacetamide, 0.04 I~l/ml diisopropylfluorophosphate, pH 4.9, and applied to an 8-ml DEAE Sephacel 
column equilibrated with the same 8 M urea buffer. After a 150-ml wash with this equilibration buffer, the column is eluted with a 150-ml 
linear gradient of NaC1. The gradient is formed with 75 ml of equilibration buffer and 75 ml of the same buffer containing 1.4 M NaCI 
instead of 0.11 M. 2.0-ml fractions were collected and the flow  rate was 28 ml/h. Each point on the figure represents two determinations 
of  TAP-1 antigenicity and three determinations of  GAG and protein concentration. For more experimental details see Materials and Methods. 
fractions (115-134, Fig. 2) was 5.7 +  0.5 (SEM). The specific 
activity of this peak increased 91-fold compared with the 
starting material. The total recovery was 0.41%  (Table I). 
The TAP-1 isolated from DEAE Sephacel appears to be at 
least 86%  pure by SDS-PAGE.  An electrophoretogram of 
this TAP-1 preparation labeled with 1251 is shown in lane E 
of Fig.  3.  (Iodinations were done in the presence of 4  M 
guanidine or 8 M urea in CHAPS to ensure maximum acces- 
sibility of tyrosine residues to label.) As seen in the figure, 
TAP-1 enters only the very top of  the 2.4-8% polyaerylamide 
gel, most likely due to its very high molecular weight (over 
1 million as discussed below). It is the only major compo- 
nent in the preparation. The radioactivity at the front of the 
gel corresponds to molecular weights <22,000 and does not 
resolve into discrete components on lower percentage gels 
(data not shown). Densitometry of lane E shows that the mi- 
nor components on the gel make up only 14 % of the total ra- 
dioactivity. In some preparations a smaller molecular weight 
(•500,000)  antigenic component was also present (as indi- 
cated by the immunoprecipitation of this smaller molecule). 
From preparation to preparation this minor component var- 
ied from 4% to 30% of TAP-1. One possibility is that it is 
a breakdown product of TAP-1. 
Fig. 3 demonstrates that purified TAP-1 is the same mate- 
rial identified by the monoclonal antibody directed against 
SV4.  Partially purified TAP-l,  labeled with  125I (lane A), 
was immunoprecipitated with the anti-SV4 mAb (lane B). 
The SDS-PAGE behavior of the immunoprecipitated TAP-1 
and the TAP-1 purified by permeation chromatography, sedi- 
mentation velocity, and DEAE chromatography is identical 
(compare lanes B and E). Further, the immunoprecipitated 
TAP-1 and purified TAP-1 also migrate identically after di- 
gestion with chondroitin ABC lyase. This is apparent from 
a comparison of lanes D  and E 
As Table I shows, the difficulty in the purification of TAP-1 
was due to the large losses that occurred during the fraction- 
ation of the solubilized ECM components. The recovery was 
10% from chromatography on Sephacryl S-1000, 23 % from 
velocity sedimentation, and 22 % from ion exchange chroma- 
tography on DEAE Sephacel. These large losses are proba- 
bly due to the tendency of TAP-1 to nonspecifically adsorb 
to various surfaces.  Because the purification involves two 
chromatographic steps as well as three concentrations by ul- 
trafiltration, the overall yield from this purification scheme 
is particularly susceptible to this problem. 
TAP-1 Is a Chondroitin Sulfate Proteoglycan 
Previous characterization of TAP-1 in partially purified ex- 
tracts suggested that it is a proteoglycan. Under denaturing 
Carlson and Wight Nerve  Terminal Anchorage Protein  3079 Figure 3. SDS-PAGE  of  purified 125I-labeled  TAP-1. The autoradio- 
gram of a 2.4-8%  linear gradient polyacrylamide gel is shown 
without the stacking gel; R marks the beginning of the running gel. 
(A) TAP-I purified through the sedimentation velocity centrifuga- 
tion step. (B) An immunoprecipitation  of sedimentation velocity- 
purified TAP-l, using the anti-SV4 mAb. (C) The control for lane 
B: an attempt at the immunoprecipitation  of TAP-1 with an irrele- 
vant monoelonal antibody. (D) TAP-1 after first immunoprecipita- 
tion (as in lane B) and then digestion with chondroitin ABe lyase. 
(E) TAP-1 purified through the chromatographic step of DEAE 
Sephacel. (F) DEAE-purified TAP-I after chondroitin ABC lyase 
digestion. Latms  A-D and E and F represent two separate gels. The 
standards used were myosin (200 kD),  ~galaetosidase (116 kD), 
phosphorylase B (92 kD), and BSA (66 kD). 30-50 BI of sample 
was applied to each gel lane. 
conditions it was found to behave as a  very large, highly 
negatively charged molecule (Carlson et al.,  1986). 
When TAP-1 was exposed to chondroitin ABe lyase, its 
mobility on SDS-PAGE changed substantially. Intact TAP-1 
just enters a 2.4-8% gradient gel (Fig. 3, lanes B and E); 
enzymatic digestion of the GAG side chains causes TAP-1 to 
move with a significantly greater mobility (Fig. 3, lanes D 
and F). 
To determine whether any other GAG chains were present 
in TAP-l, the purified molecule was digested with a variety 
of glycosaminoglycan lyases and subjected to SDS-PAGE. 
We considered this a real possibility, since the chondroitin 
ABC lyase digested TAP-1 continued to migrate as a very 
broad band, suggesting that the molecule was still heavily 
glycosylated. Both chondroitin ABC lyase and chondroitin 
AC lyase digestion changed the mobility of TAP-1 to about 
the same extent (Fig. 4, lanes b and d). This indicates that 
TAP-1 contains chondroitin-4-or 6-sulfate and not dermatan 
sulfate. The AC lyase will digest only  4- or 6-chondroitin sul- 
fate chains, while the ABC lyase will digest dermatan sulfate 
as well as the chondroitin sulfates (Saito et al.,  1968). 
We found that heparitinase also changed the mobility of 
TAP-I  (Fig. 4,  lanes h and k). This enzyme is specific for 
heparan sulfate chains. Most likely, however, this result was 
simply due to a chondroitin sulfate lyase contaminating the 
heparitinase.  The mobility shift produced by heparitinase 
was smaller than the shift produced by chondroitinase diges- 
tion (compare lanes h  and i in Fig. 4).  When TAP-I  was 
digested with both heparitinase and chondroitin ABe lyase, 
the mobility change was no greater than that caused by chon- 
droitinase alone (Fig. 4, lane g). Such a result could be pro- 
duced from a partial digestion of chondroitin sulfate chains 
by low amounts of a  contaminating chondroitinase in the 
heparitinase preparation.  This explanation was confirmed 
when we found that the presence of chondroitin sulfate (1.9 
Bg/ml) in the reaction mixture inhibited the heparitinase- 
induced mobility change in TAP-l,  whereas heparan sulfate 
at the same concentration had no inhibitory effect (compare 
lanes m and k, Fig. 4). Presumably, the high concentration 
of unlabeled chondroitin sulfate protected the very small 
amounts of t25I-TAP-1 from digestion by saturating the con- 
taminating enzyme with substrate. Tl}is contaminating  activ- 
ity must be at relatively low concentration. Parallel reactions 
with the same GAG and heparitinase concentrations showed 
complete digestion of heparan sulfate, but little change in 
chondroitin sulfate concentration when analyzed by cellu- 
lose acetate electrophoresis. The overall conclusion is that 
TAP-I  does not contain heparan sulfate chains. 
Both heparinase (Fig. 4, lane  f), specific for heparin and 
heparinlike sequences in heparan  sulfate, as well as ker- 
atanase (Fig. 4, lane c), specific for keratan sulfate, had no 
effect on TAP-1. (Under these same conditions, heparinase 
and keratanase showed complete digestion of  their GAG sub- 
strates.) Thus, TAP-I does not appear to contain heparin or 
keratan sulfate. 
The chondroitin ABC lyase digested material most likely 
contains carbohydrate side chains in addition to chondroitin 
sulfate, in that even after digestion it migrates as a very broad 
band on SDS gels. A combination of chondroitin ABC lyase 
and N-glycanase or neuraminidase failed to affect the mobil- 
ity of TAP-I compared with chondroitin ABCase alone (data 
not shown). Because TAP-1 does not migrate as a discrete 
protein on SDS-PAGE even after these digestions, the mole- 
cule is probably still heavily glycosylated. Presumably it 
contains other O-linked sugars, as has been demonstrated for 
a variety of other proteoglycans (HascaU and Hascall, 198t). 
Size of  TAP-1 and Its Chondroitin Sulfate Chains 
To determine an approximate size for the entire TAP-1 mole- 
cule by column chromatography, we subjected TAP-I to gel 
filtration on Sephacryl S-500  in 4  M guanidine-HCl/0.2% 
CHAPS. On the same column a smooth muscle cell chon- 
droitin  sulfate proteoglycan was  chromatographed  which 
had a molecular weight estimated to be 1.26  x  106 (Iozzo et 
al.,  1982). These chromatographic separations are shown 
on Fig. 5.  TAP-1 eluted with a K~ of 0.27 and the smooth 
muscle cell proteoglycan with a K,v of 0.21. Therefore, we 
would expect TAP-1 to have a molecular weight similar to the 
smooth muscle proteoglycan. 
The size of  the GAG side chains was estimated  by gel filtra- 
The Journal of Cell Biology, VoMme 105, 1987  3080 Figure 4. SDS-PAGE of TAP-I after digestion with glycosaminoglycan lyases. Purified ~2SI-TAP-1  is shown before and after digestion with 
several glycosaminoglycan lyases on 2.4-8%  linear gradient polyacrylamide gels; the resulting autoradiograms axe shown.  TAP-1 was 
digested with the following enzymes: (a) no enzyme, (b) chondroitin AC lyase, (c) keratanase, (d) chondroitin ABC lyase, (e) no enzyme, 
(f) heparinase, (g) chondroitin ABC lyase and heparitinase, (h) heparitinase, (i) chondroitin ABC lyase, (j) no enzyme, (k) heparitinase 
and 1.9 ttg/ml heparan sulfate, (l) heparitinase,  1.9 ttg/ml heparan sulfate, and 1.9 ttg/ml chondroitin sulfate-type c, (m) heparitinase and 
1.9 ~tg/ml chondroitin sulfate-type C, and (n) no enzyme. Only chondroitin ABC lyase (d, g, i), chondroitin AC lyase (b), and heparitinase 
(g, h, and k) cause a change in the mobility of TAP-1. However, the change in mobility due to heparitinase must be due to a contaminating 
chondroitin sulfate lyase, because no shift was observed when the reaction mixture contained 1.9 ~tg/ml chondroitin sulfate (l and m). The 
same concentration of heparan sulfate did not interfere with the heparitinase digestion of TAP-1 (k). The other glycosaminoglycan lyases, 
which showed no effect on TAP-I, gave complete digestion of their normal GAG substrates at a concentration of 1.9 ~tg/ml under the same 
reaction conditions used for TAP-1. BSA, which was included in the digestion buffer at 50 lxg/ml (1.5 ttg per lane), showed no evidence 
of protease activity for any of the digestions on the Coomassie-stained SDS gel. All digestions contained protease inhibitors. The standards 
used were myosin (200 kD), ~galactosidase (116 kD), phosphorylase B (92 kD), and BSA (66 kD). S and R indicate the beginnings of 
the stacking gel and running gel, respectively. The ~25I-TAP  used for these digestions was iodinated with 125I  after the velocity sedimenta- 
tion step (Table I) and then purified by chromatography on DEAE sephacel. 30-50 I~1 of sample was applied to each gel lane. For further 
experimental details see Materials and Methods. 
tion on Sepharose CL-6B. The GAG chains were first cleaved 
from TAP-1 by alkaline borohydride treatment.  The elution 
profile for one such chromatography is shown in Fig. 6. The 
results  of three cleavages and chromatographic  separations 
give  a  Kay for the  major peak of 0.36  +  0.02  (SEM);  the 
Kay's for leading  and  trailing half heights  were 0.26  +  0.01 
(SEM) and 0.53  +  0.01 (SEM), respectively. Using the chon- 
droitin sulfate calibration curves of Wasteson (1971) for mo- 
lecular  weight  vs.  Kay, we  calculated  the  corresponding 
molecular  weights  to  be 42,000  (+4,000)  with  a  range  of 
70,000-17,000  for the leading and trailing edges of the peak. 
In order to directly identify the GAGs of TAP-l, the GAGs 
isolated by chromatography on Sepharose CL-6B were sub- 
jected to cellulose acetate electrophoresis. The results of this 
electrophoresis  are shown in the inset of Fig.  6.  One band 
is seen that comigrates with chondroitin-4- and 6-sulfate, but 
not with dermatan sulfate. This agrees with the glycosamino- 
glycanase  digestion  experiments  discussed  earlier,  which 
demonstrate that TAP-1 is completely sensitive to chondroi- 
tin AC lyase. 
A  minor GAG, migrating more slowly, is also present on 
cellulose acetate electrophoretograms of TAP-1 GAGs. This 
component  is present  at  ~10%  of the level of chondroitin 
sulfate.  However,  it is not readily apparent in Fig.  5  and is 
presumably just a  contaminant of the TAP-1  preparation. 
The model of TAP-1 which emerges from its biochemical 
characterization is that of a large proteoglycan of about a mil- 
lion  molecular  weight,  possessing  chondroitin  sulfate  side 
chains  with an average molecular weight of 42,000. 
Electron Microscopic Visualization of TAP-1 
Individual proteoglycan molecules have distinctive morpho- 
logic features which can be seen in the electron microscope 
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Figure  5.  Chromatography of TAP-1 and  a  1.26  x  106-mol wt 
smooth  muscle  chondroitin  sulfate  proteoglycan  on  Sephacryl 
S-500. Two separate chromatographic separations performed on the 
same column are shown: one with a guanidine-HCl ECM extract 
containing TAP-1 (o), and one with a 35SO4-1abeled smooth mus- 
cle cell layer extract  (A)  which contained a  1.26  ￿  106-mol  wt 
chondroitin sulfate proteoglycan (Chang et al.,  1983; Iozzo et al., 
1982). The smooth muscle cell proteoglycan elutes at a K~ of 0.21 
(arrow A) and TAP-1 elutes at a K,~ of 0.25 (arrow B). A smaller 
dermatan sulfate proteoglycan is also present in the smooth muscle 
cell extract and ehtes at 0.7 K,~. The 0.9 g of electric organ ECM 
fraction was solubilized  with 6 M guanidine-HCl (as described in 
Materials  and Methods) and applied  to a 350-ml (2.6  x  66 cm) 
Sephacryl S-500 column in 9 ml. The column was equilibrated  with 
4 M guanidine-HCl, 50 mM Hepes, 0.2%  CHAPS, 200 mg/liter 
iodoacetamide,  15 I~l/liter diisopropylfluorophosphate,  400 gg/liter 
each of pepstatin,  leupeptin,  and cbymostatin, pH 7.0. The smooth 
muscle cell extract  consisted  of 1 ml of carrier proteoglycan (D1 
fraction of rat chondrasarcoma extract [Chang et al.,  1983]), 4 ml 
of 35SO4-1abeled smooth muscle layer, and 6 ml of 6 M guanidine- 
HCI extraction buffer (see Materials  and Methods).  10 gl of this ex- 
tract were applied  to the column. The chromatography was per- 
formed at a flow rate of  30 ml/h and 3.0-ml fractions were collected. 
The II0 and the VT for the column were determined by the elution 
profiles  of sheared  salmon  sperm  DNA  and  dCT32p (or  free 
35SO4), respectively.  The ehtion of the free 35SO4 counts per min- 
ute contained in the smooth muscle cell extract is not shown in the 
figure. 
(Hascall and Hascall,  1981). They are described as having a 
"bottlebrush" appearance.  We wished to determine if TAP-1 
has such a structure and to learn the dimensions of the pro- 
posed structure. DEAE Sephacel-purified TAP-1 was spread 
on carbon-coated grids, subjected to low angle rotary shad- 
owing,  and examined in the electron microscope. 
Inspection of the purified molecules (n  =  152) spread on 
a carbon film revealed a predominance of the expected "bot- 
tlebrush" structures with an average long axis (tip to tip) of 
345  +  17 nm and an average diameter (at the widest point) 
of 214  -t-  19 nm. Fig. 7, a-e shows some representative ex- 
amples of the types of structures which we observed.  Fre- 
quentiy, at one end of the molecule, a globule taillike region 
was seen associated with the core of the molecule. A central 
core (not including the taillike portion) measuring ,,o320  + 
38 nm could be recognized for most well-spread molecules, 
to which were attached 20 +  2 side projections averaging 113 
+  5 nm in length. Occasionally, these individual molecules 
Figure 6. Chromatography of TAP-I GAG side chains on Sepharose 
CL-6B released by alkaline borohydride cleavage. GAG concentra- 
tion (o) is plotted as determined by a quantitative Alcian blue assay 
on DEAE nitrocellulose.  The Sepharose CL-6B column (133  ￿ 
0.7 cm) was equilibrated  with 0.2 M NaCI, 50 mM Hepes,  0.02% 
sodium azide, pH 7.0; the flow rate was 3.8 ml/h, and 0.75-ml frac- 
tions were collected.  The  II0 and  Vr of the column were deter- 
mined by the elution of blue dextran and NaUSI, respectively.  The 
K~ for each fraction was calculated by using these values. Two ad- 
ditional  alkaline  borohydride cleavages  and  resulting  chromato- 
graphic separations gave essentially the same results as shown here. 
Here 12 ~tg of protein of purified TAP-1 were subjected to 15 elim- 
ination  and applied  to the column. (Inset)  Celldose acetate elec- 
trophoresis  of TAP-1 GAGs isolated  by chromatography on this 
Sepharose  CL-6B column. The entire chromatographic peak was 
pooled and concentrated for the analysis. Autoradiograms of mRuthe- 
nium Red-stained electrophoretograrns  are shown.  (Lane 1) Der- 
matan sulfate (CS-B); lanes 2 and 4, TAP-1 GAGs; (lane 3) chon- 
droitin-4-  and  6-sulfate  (CS-A,C).  Or  identifies  the  origin;  the 
direction of travel is toward the anode. 
were  present  as  clusters  and  associated  with  one  another 
through their tail-like projections  (Fig.  7  e). 
Discussion 
During  nerve  regeneration  at the neuromuscular junction, 
the nerve terminal reforms the exocytotic zones of its plasma 
membrane opposite a specialized region of the postsynaptic 
membrane. It has been shown that the positional cues which 
the nerve terminal detects are actually present in the synaptic 
basal lamina (Sanes et al., 1978; Glickman and Sanes, 1983). 
A useful hypothesis is that the recognition of  these ECM cues 
occurs  via presynaptic  integral  membrane  proteins  which 
bind these ECM components. That is, this recognition prob- 
ably occurs through a  subset  of nerve terminal  anchorage 
proteins. Little is known about the number and kind of mole- 
cules which serve as anchorage proteins  for the nerve ter- 
minal. 
Previously it was shown that TAP-1 has the properties of a 
nerve terminal anchorage protein (Carlson et al., 1986). This 
protein was identified not from the neuromuscular junction, 
but from the related synapse of electric organ. Several prop- 
erties  suggest that TAP-1 is an anchorage protein.  (a) It is 
exclusively associated with the nerve terminal plasma mere- 
The Journal of Cell Biology, Volume  105,  1987  3082 Figure  7.  Electron microscopic visualization of TAP-1. 
Electron micrographs  of  purified TAP-1 spread on carbon- 
coated grids and rotary shadowed at low angle (10~ 
(a-d) Typical  profiles  of  individual  molecules. Each mol- 
ecule possessed a globular region (arrow) at one end. (a) 
x98,000; (b) xl01,000; (c) x103,000; and (d) x99,000. 
Occasionally, individual molecules were associated with 
one  another  through  their  "taillike" projections:  (e) 
x105,000. Bar, 0.25 [am. 
brane throughout the synaptic region, as determined by im- 
munocytochemistry at the electron microscopic level (Carl- 
son et al., 1986; Kelly et al., 1987). (b) The molecule binds 
lipids and can be incorporated into liposomes, indicating that 
it behaves as an integral membrane protein. (c) The molecule 
is tightly associated with an electric organ ECM fraction, 
Such characteristics suggest that this molecule is an integral 
membrane protein of the nerve terminal and acts as a link to 
the ECM. However, as yet we have no direct functional evi- 
dence that it fulfills this role. 
We  have  isolated  TAP-1 to  at  least  86%  purity.  The 
methods utilized to purify TAP-1 were based on the analyti- 
cal procedures previously used to characterize this antigen 
in a less pure preparation (Carlson et al., 1986). Not surpris- 
ingly then, the molecule has the same physical properties 
(chromatographic size, sedimentation rate, and charge den- 
sity) as the impure antigen. For example, at the last step of 
the purification TAP-1 elutes at about 0.7 M NaCI at pH 4.9. 
These are the same conditions required for the elution of 
the impure antigen (Carlson et al.,  1986). Previously, 65 % 
of TAP-1 in an impure preparation was found to behave as 
an  integral  membrane protein  by liposome reeonstitution 
(Carlson et al.,  1986). About 80 % of the purified TAP-1 is 
found to behave as an integral membrane protein (Iwata, M., 
and S. S. Carlson, unpublished observations). This was de- 
termined by the buoyant density of TAP-1 on CsCI density 
gradients containing Triton X-100 (Kjellen et al.,  1981). 
TAP-1 is a chondroitin sulfate proteoglycan of large hydro- 
dynamic size. In the electron microscope TAP-1 has the typi- 
cal "bottlebrush" morphology of a proteoglycan. In overall 
shape and size, the bottlebrush structure resembles similar 
structures of isolated and purified chondroitin sulfate con- 
raining proteoglycans from cartilage (Hascall and Hascall, 
1981), blood vessels (Kapoor et al.,  1986),  skeletal muscle 
(Pechak et al.,  1985), and arterial smooth muscle cell cul- 
tures (Wight and Hascall, 1983). The presence of a globular 
region at one end of the molecule is similar to preparations 
of  the large chondroitin sulfate proteoglycans from cartilage. 
This domain is thought to represent a GAG-free area of the 
core protein involved in binding hyaluronic acid in the for- 
mation of high molecular weight aggregates  (see  review, 
Hassel et al., 1986). Whether TAP-1 is capable of interacting 
with hyaluronic acid is not known. It is interesting to note 
that a small fraction of the TAP-1 molecules spread for elec- 
tron microscopic observation appear to interact with one an- 
other  through  these  extended  "taillike" regions.  Because 
TAP-1 has the properties of an integral membrane protein 
(Carlson et al.,  1986), TAP-1 might be associating nonspe- 
cifically  through its hydrophobic domain. This is a consider- 
ation because TAP-1 was spread under low detergent condi- 
Carlson and Wight Nerve Terminal Anchorage Protein  3083 Table II. Comparison of  the Molecular Properties 
for TAP-1 Estimated from Biochemical and Electron 
Microscopic Data 
Electron 
Biochemical  microscopic 
Property  estimate  estimate 
Relative mol wt of GAG  42,000  50,000 
side chains  (17,000-70,000) 
Relative mol wt of  106  1.2  x  106 
intact molecule 
GAG/protein  5.7  + 0.5  5.7 
(Izg/Izg) 
tions. The ability of this molecule to associate with itself or 
with other matrix compounds needs further investigation. 
Both the morphologic and the biochemical data indicate 
that TAP-1 is a large (>106 D) molecule. If one assumes that 
the long axis of the "bottlebrush structure" represents the 
protein core, one can calculate the relative molecular weight 
of the core to be =180,000  (Hascall,  1980).  Similarly, if the 
side projections represent one or more GAG chains, an aver- 
age length of 113 nm would give a theoretical relative molec- 
ular weight estimate of 50,000 for the GAG chain, assuming 
that a disaccharide has an average length of 1 nm and a rela- 
tive molecular weight of 440 (Hascall, 1980). The behavior 
of TAP-1 chondroitin sulfate chains on Sepharose CL-6B in- 
dicates an average molecular weight of 42,000 (Wasteson et 
al.,  1971), close to the morphologic estimate.  In that each 
molecule possesses 20  +  2  side projections, a  theoretical 
relative molecular weight of the entire proteoglycan can be 
calculated to be 20 x  50,000  +  180,000 =  1.2  x  106. (How- 
ever, it may be that this relative molecular weight is an un- 
derestimate because TAP-1 may also contain N- and O-linked 
oligosaccharides which are not resolved in the electron mi- 
croscope [Hascall and Hascall, 1981].) This model of TAP-1 
is further supported by the fact that both the morphologic and 
biochemical data indicate a similar GAG to protein ratio. The 
morphologic data  indicate  a  ratio  equal  to  (1,200,000  - 
178,000)/178,000 =  5.7 (Table II). This value is identical to 
one which can be measured biochemically (5.7  •  0.5  ~tg/ 
~tg). The biochemical estimate was calculated from the data 
in Fig. 2. 
The model of TAP-l, which emerges from the biochemical 
and electron microscopic data, is that of an extremely large 
molecule. Visualized in two dimensions, as it is in the elec- 
tron micrographs of the spread molecule, TApol is 345 nm 
long and 214 nm wide. This is quite large compared with the 
electric organ synaptic cleft and the synaptic basal lamina of 
which TAP-1 is presumably a part. The synaptic cleft mea- 
sures about 60 nm; thus, TAP-1 could easily touch both pre- 
and postsynaptic cells as  diagrammed in Fig.  8.  Unfortu- 
nately, none of  the precise details of  the extracellular location 
of  TAP-1 in the synaptic basal lamina have been immunocyto- 
chemically  determined.  The  placement  of TAP-1 in  the 
opaque central zone of the basal lamina in the lower section 
of Fig. 8 is simply a hypothesis. However, the comparison 
shown  in  Fig.  8  suggests  that  TAP-1 could be  making  a 
significant structural contribution to the basal lamina that runs 
through the cleft. The actual space that the molecule could 
occupy might be reduced considerably if the protein were 
Figure 8. (Upper diagram) Comparison of the size of TAP-1 and 
the synaptic cleft. The two-dimensional image of a TAP-1 molecule 
derived from electron microscopy is shown next to a cross section 
of the electric organ synapse; both the nerve terminal and TAP-1 
are drawn to scale. TAP-1 is large enough to span the synaptic cleft. 
Thus, it could make a major structural contribution to the nerve ter- 
minal basal lamina. SyBL, Synaptic basal lamina; NT, nerve termi- 
nal; PSC, postsynaptic cell. (Lower  diagram) Hypothetical place- 
ment of TAP-1 in the synaptic cleft. A small three-dimensional cut- 
away section of  the synaptic cleft containing TAP-1 is shown. TAP-1 
is represented as a transmembrane protein in the figure. However, 
it has only been shown to have the properties of an integral mem- 
brane protein (Carlson et al., 1986); it has not yet been determined 
whether it spans the nerve terminal membrane bilayer. 
complexed with other proteins. On the other hand, the large 
hydrodynamic volumes characteristic of the proteoglycans 
might be important for filling the synaptic cleft and holding 
the pre- and postsynaptic cells a  fixed distance apart.  The 
ability of the large cartilage proteoglycans to act as cushions 
and reversibly resist compressive force is well known (Has- 
call and Hascall,  1981). Proteoglycans might do this and at 
the same time provide an aqueous environment for the rela- 
tively unobstructed diffusion of neurotransmitters. 
Several questions remain. The monoclonal antibody used 
to identify TAP-1 was originally raised against synaptic vesi- 
cles from the electric organ (Caroni etal.,  1985). The char- 
acteristics of this antigenic site (SV4) are (a) it is present 
on TAP-1 and the synaptic vesicle proteoglycan in electric or- 
gan, (b) it is carbohydrate in nature, (c) it is a product of the 
nerve as indicated by axonal transport studies, and (d) it is 
enriched in the neurons innervating the electric organ (Caroni 
etal.,  1985; Carlson etal.,  1986).  The exact nature of this 
antigenic site (SV4) remains to be elucidated. Further, the 
relationship between the synaptic vesicle proteoglycan and 
TAP-1 is not completely understood. It has been suggested 
that the much smaller synaptic vesicle molecule represents 
a  breakdown product of TAP-l, picked up by the synaptic 
vesicle (Kelly et al.,  1987; Carlson et al.,  1986).  However, 
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TAP-1 is a chondroitin sulfate proteoglycan, whereas the syn- 
aptic vesicle  proteoglycan  is thought to be in the heparin/ 
heparan sulfate family (Carlson and Kelly, 1983; Stadler and 
Dowe,  1982). Maybe TAP-1 and the synaptic vesicle proteo- 
glycan are unrelated polypeptides which share a unique car- 
bohydrate for some other function, such as intracellular sort- 
ing (Kelly et al.,  1987; Carlson et al.,  1986). 
Because TAP-1 appears to be an integral membrane pro- 
tein, it makes sense that it is a product of the presynaptic cell 
in whose plasma membrane bilayer it resides.  However, an 
ambiguity  exists  in  the  interpretation  of previous  axonal 
transport studies of the SV4 antigen (Caroni et al.,  1985). 
These were done before it was realized that two molecules 
bearing the SV4 antigen exist in electric organ: the synaptic 
vesicle proteoglycan and TAP-1. Because the axonally trans- 
ported  SV4 antigens  were  identified  only by their antige- 
nicity, we cannot be certain that both antigens (the synaptic 
vesicle proteoglycan and TAP-l) were being axonally trans- 
ported. It is possible that only the synaptic vesicle proteogly- 
can is being transported and TAP-1 is made by the postsynap- 
tic cell. Entertaining this hypothesis, however, also involves 
the somewhat unlikely idea that one cell is contributing an 
integral membrane protein to another. 
TAP-1  is one of the first purified nerve terminal integral 
membrane proteins which is thought to link the nerve termi- 
nal to the ECM. Integral membrane cell surface proteogly- 
cans  which  are  thought to  act  as  anchorage  proteins  are 
known in a number of nonneural tissues, however (Hassel et 
al.,  1986; Hook et al.,  1984; Woods et al.,  1985; Rapraeger 
et al.,  1987; Garrigies et al.,  1986). Presumably TAP-1 binds 
postsynaptic anchorage proteins directly or indirectly through 
other  ECM  proteins  completing  a  pre-  to  postsynaptic 
bridge.  Another element of a  nerve terminal-postsynaptic 
ECM bridge has also been isolated from electric organ. This 
protein,  known as agrin (Magill  et al.,  1986;  Reist et al., 
1986), will cluster acetylcholine receptor and acetylcholin- 
esterase on the surface of myotubes. Its presence in the neu- 
ronal cell bodies of electric organ suggests that it, like TAP-l, 
is a product of the presynapfic cell (Magill et al., 1986). Un- 
like TAP-l, it is presumably not a membrane protein because 
it does not require detergent for its solubilization (Godfrey 
et al., 1984). Monoclonal antibodies that immunoprecipitate 
the agrin acetylcholine receptor-clustering activity identify 
two polypeptides with relative molecular weights of 70,000 
and 95,000 (Magill et al.,  1986). Both TAP-1 and agrin are 
purified from the same electric organ ECM preparation.  It 
is not known whether they interact with one another. 
An intriguing question for TAP-1 is: does it act as a general 
synaptic glue or a specific adhesive? In the former case, one 
might expect TAP-1 to be bound by the ECM only via pro- 
teins which are not synaptically  localized,  such as laminin 
(Sanes and Chiu, 1983). In the latter case, one might expect 
binding by synapse-specific  proteins as well. 
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Note added in proof. After this manuscript was submitted, Kiene and St,ad- 
ler reported the association of the synaptic vesicle proteoglycan with an 
electric organ ECM fraction (Kiene, M.-L., and H. Stadler.  1987. EMBO 
(Eur. MoL  Biol.  Organ.)Z  6:2217-2221). We find that the majority of the 
synaptic vesicle antigen (SV4)  in the ECM  fraction  is actually  due to 
the presence of TAP-I (Carlson et al.,  1986).  However, we also find low 
amounts of the smaller synaptic vesicle proteoglycan is also present (Iwatu, 
M., and S.  S.  Carlson, unpublished observations). 
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